L-Threonine deaminase as a possible antitumor agent

Area of Science:

• Biochemistry
• Enzymology
• Cell Biology

Background:

• L-threonine deaminase is an enzyme involved in amino acid metabolism.
• Cancer cells often exhibit altered metabolic pathways.
• Investigating enzyme-based therapies for cancer is an emerging area.

Purpose of the Study:

• To evaluate the cytotoxic effects of purified sheep liver L-threonine deaminase on cancer cell lines.
• To assess the in vivo efficacy of L-threonine deaminase in reducing plasma L-threonine levels.
• To determine the pharmacokinetic profile of L-threonine deaminase in circulation.

Main Methods:

• In vitro cytotoxicity assays using murine leukemia cell lines (e.g., WEHI-3, P388) and control cell lines (L cells, human fibroblasts).
• Intravenous injection of L-threonine deaminase into mice to measure plasma L-threonine concentrations.
• Pharmacokinetic analysis to determine the enzyme's half-life in the bloodstream.

Main Results:

• L-threonine deaminase exhibited significant cytotoxicity against two murine leukemia cell lines.
• No cytotoxic effect was observed on normal L cells or human fibroblasts.
• In vivo administration of the enzyme led to a 90% reduction in plasma L-threonine concentration in mice.
• The enzyme demonstrated a half-life of 1.5 hours in the circulation.

Conclusions:

• Purified L-threonine deaminase possesses selective anti-leukemic activity in vitro.
• The enzyme effectively depletes circulating L-threonine in vivo, suggesting potential therapeutic applications.
• The rapid clearance of L-threonine deaminase indicates a need for strategies to prolong its activity if used therapeutically.